A mid-stage trial of the vaccine in South Africa, where a new variant of the virus is common, showed 60 per cent effectiveness among people who did not have HIV.
Novavax is already stockpiling vaccine at six operating manufacturing locations, and said it expects a total of eight plants in seven countries to produce at the rate of 2 billion doses per year, including from the Serum Institute of India.
COVID-19 vaccine 89.3% effective in U.K. trial but less so in South Africa, Novavax says Sorry, but your browser needs Javascript to use this site. If you re not sure how to activate it, please refer to this site: https://www.enable-javascript.com/
A volunteer in Novavax’s South Africa trial is examined by a doctor before receiving an injection at Wits RHI Shandukani Research Centre, in Johannesburg, in December. | JOAO SILVA / THE NEW YORK TIMES
Reuters Jan 29, 2021
Chicago – Novavax Inc said Thursday its novel coronavirus vaccine was 89.3% effective in preventing COVID-19 in a trial conducted in the United Kingdom, and was nearly as effective in protecting against the more highly contagious variant first discovered in the country, according to a preliminary analysis.
Serum Institute seeks approval to conduct trial for Novavax COVID-19 vaccine
Last year in September, Novavax had announced its deal with Serum Institute in order to produce 2 billion doses of COVID-19 vaccines
BusinessToday.In | January 29, 2021 | Updated 16:49 IST
Novavax s protein-based coronavirus vaccine was 89.3 per cent effective in preventing coronavirus in a trial conducted in the UK
After successfully manufacturing the University of Oxford-AstraZeneca s Covishield vaccine in India, Serum Institute of India (SII) has now applied to India s drug controller to conduct a trial of Novavax Inc s COVID-19 vaccine. Serum Institute s CEO Adar Poonwalla told news agency Reuters that he is expecting a decision on the Indian trial on Novavax s vaccine soon.